Stroke prevention in atrial fibrillation: Do we still need warfarin?

Department of Neurology and Stroke Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Current opinion in neurology (Impact Factor: 5.31). 12/2011; 25(1):27-35. DOI: 10.1097/WCO.0b013e32834e604a
Source: PubMed


Oral anticoagulation with vitamin K antagonists (warfarin, phenprocoumon) is successful in both primary and secondary stroke prevention in patients with atrial fibrillation, yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26%. However, these agents have a number of well documented shortcomings. Acetylsalicylic acid (ASA) reduces the relative risk of stroke by a nonsignificant 19% compared with placebo, and increased bleeding risk offsets any therapeutic gain from the combination of ASA with clopidogrel. This review describes the current landscape and developments in stroke prevention in patients with atrial fibrillation, with special reference to secondary prevention.
A number of new drugs for oral anticoagulation that do not exhibit the limitations of vitamin K antagonists are under investigation. These include direct factor Xa inhibitors and direct thrombin inhibitors. Recent studies (RE-LY, ROCKET-AF, AVERROES, ARISTOTLE) provide promising results for new agents, including higher efficacy and significantly lower incidences of intracranial bleeds compared with warfarin. The new substances show similar results in secondary as in primary stroke prevention in patients with atrial fibrillation.
New anticoagulants add to the therapeutic options for patients with atrial fibrillation, and offer a number of advantages over warfarin, for both the clinician and patient, including a favourable bleeding profile and convenience of use. Consideration of these new anticoagulants will improve clinical decision making.

1 Follower
13 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Catheter ablation of atrial fibrillation (AF) has evolved as a potential curative option for drug-refractory AF in recent years. AF not only causes physical morbidity but also jeopardizes the mental and social health of the patient as well as predisposing the patient to increased risk of thromboembolic events. Therefore, the primary end points of AF ablation have been restoration of sinus rhythm, improvement in the quality of life and lowering the risk of cerebrovascular accidents. However, even in the best hands, AF ablation is yet to be a total success. Several risk factors of AF and parameters of catheter ablation influence the short- and long-term ablation outcome. This article reviews all the information that has been contributed by prominent independent researchers over the last decade.
    Expert Review of Cardiovascular Therapy 07/2012; 10(7):889-900. DOI:10.1586/erc.12.62
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-valvular atrial fibrillation (NVAF) is the main cause of cardioembolic stroke. Classically, prevention consists of oral antivitamin-K anticoagulants (AVK), which, despite their demonstrated efficacy, continue to be underused due to their numerous drawbacks. Recently, a new generation of oral anticoagulants has been shown to have a better safety profile and greater efficacy than AVK. The studies that have compared rivoraxaban, dabigatran and apixaban with warfarin have also included a substantial proportion of patients who had previously had a stroke. The results of the substudies performed in this population with a high risk of hemorrhagic and embolic events have been consistent with those in the overall populations in these studies. The new anticoagulants are a feasible alternative to AVK in the secondary prevention of ictus in patients with NVAF. When anticoagulant therapy is contraindicated, percutaneous closure of the left atrial appendage could be an alternative.
    Medicina Clínica 10/2012; 139:51–55. DOI:10.1016/S0025-7753(12)70043-X · 1.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Until recently, only vitamin K antagonists (VKAs) were used for long-term anticoagulation. New oral anticoagulants, with pharmacokinetic and pharmacodynamic characteristics different to VKAs, are now available for some indications. Rivaroxaban (Xarelto®) is an oral Factor Xa inhibitor approved in many countries for long-term treatment of patients with atrial fibrillation or venous thromboembolism. This article is addressed to all professionals involved in the management of treated patients to highlight the characteristics of rivaroxaban and provide practical guidance on management of treated patients. Areas covered: This article is based on a consensus of specialists involved in the management of anticoagulant treatment, including thrombosis experts, cardiologists, neurologists, emergency medicine specialists, and general practitioners. The authors performed a nonsystematic review of the literature, and expressed guidance statements based on the results of the review as well as personal experience. Expert opinion: Availability of new anticoagulant drugs, including rivaroxaban, is an important step forward to allow easier, more effective, and safer long-term anticoagulation in patients in whom adequate anticoagulation is currently denied due to the limitations of VKAs. However, given their totally new properties, associated risks, and expected broad clinical use, expert professionals and manufacturers must urgently tackle a series of issues.
    Expert Opinion on Pharmacotherapy 02/2013; 14(5). DOI:10.1517/14656566.2013.773310 · 3.53 Impact Factor
Show more

Similar Publications